1|0|Public
50|$|<b>Befetupitant</b> (Ro67-5930) {{is a drug}} {{developed}} by Hoffmann-La Roche which acts as a potent and selective antagonist for the NK1 receptor. It was originally developed as a potential antiemetic drug, though development was ultimately discontinued after a related drug netupitant was deemed to be more suitable for clinical development. <b>Befetupitant</b> has however continued to be researched for other possible applications such as treatment of corneal neovascularization.|$|E

